Business Context and Reporting Period
Company: Vericel Corporation (VCEL)
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2026
Context: The filing announces the Company's participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. It serves to disclose preliminary, unaudited financial results for the fiscal year ended December 31, 2025, which were issued via a press release (Exhibit 99.1).
Key Financial Metrics
The filing references a press release containing estimates for the following fiscal year 2025 metrics, but does not provide the specific numerical values within the text of this 8-K:
- Estimated full-year revenue
- Preliminary net income
- Gross margin percentage
- Adjusted EBITDA margin
- Cash and investments balance as of December 31, 2025
Note: The filing explicitly states that these figures are preliminary, unaudited, and subject to change. PricewaterhouseCoopers LLP has not audited or reviewed this data.
Material Changes
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year analysis.
Guidance, Outlook, and Risks
- Outlook: The Company provided "additional financial and business updates" in the referenced press release, though specific forward-looking statements are not detailed in this 8-K text.
- Risks and Contingencies: The Company warns that actual results may differ materially from the preliminary estimates because the financial statements for the year ended December 31, 2025, have not been finalized or audited.
- Legal Status: The information in Items 2.02 and 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific numerical values of revenue, net income, and margins.
- Verify the final audited financial statements once issued to confirm the accuracy of the preliminary estimates.
- Monitor the Company's presentation at the J.P. Morgan Healthcare Conference for further business updates.
- Confirm that the preliminary cash and investments balance aligns with the Company's liquidity needs and debt obligations.